Publications by authors named "C J Silber"
Article Synopsis
- Major depressive disorder (MDD) significantly impacts health-related quality of life (HRQoL), and this study examined how the neuroactive steroid zuranolone affects HRQoL using the Short Form-36v2 Health Survey (SF-36v2).
- Adult patients with MDD were randomly assigned to receive either zuranolone or a placebo for two weeks, with HRQoL assessed across various domains at Day 15 showing substantial improvements for those treated with zuranolone, particularly in areas like Mental Health and Vitality.
- The results suggest that zuranolone leads to rapid and meaningful HRQoL enhancements compared to placebo, although the small sample size may limit generalizability and other factors could influence HRQoL
Bayesian Machine Learning for Efficient Minimization of Defects in ALD Passivation Layers.
ACS Appl Mater Interfaces
November 2021
Article Synopsis
- Atomic Layer Deposition (ALD) provides a high-quality, conformal coating ideal for protecting sensitive materials, but optimizing the deposition parameters is complex due to the high number of variables involved.
- Machine-learning methods, particularly Bayesian optimization (BO), have proven effective at minimizing defects in an ALD-AlO passivation layer for corrosion protection of copper, achieving optimal results in fewer than three trials.
- The study shows that with the optimized parameters, including surface pretreatment and specific deposition conditions, the corrosion resistance is significantly improved, highlighting the potential of integrating machine learning in materials science.
Article Synopsis
- This study aimed to assess the effectiveness of two doses of zuranolone (30 mg and 45 mg) in improving sleep in a phase advance insomnia model compared to a placebo.
- In a double-blind crossover study, healthy adults were tested with three treatment periods and their sleep was measured using polysomnography and questionnaires.
- Results showed that zuranolone significantly improved sleep metrics like sleep efficiency, wake after sleep onset, and total sleep time, with the drug being well tolerated overall, primarily causing mild side effects like headache and fatigue.
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
Brian I Rini Michael B Atkins Elizabeth R Plimack Denis Soulières Raymond S McDermott Cynthia G Silber
Eur Urol Oncol
April 2022
Background: Pembrolizumab plus axitinib improved efficacy over sunitinib in treatment-naive advanced renal cell carcinoma in the KEYNOTE-426 (NCT02853331) study. However, a relatively high incidence of grade 3/4 aminotransferase elevations was observed.
Objective: To further characterize treatment-emergent aminotransferase elevations in patients treated with pembrolizumab-axitinib.
Article Synopsis
- Postpartum depression (PPD) is a prevalent medical issue affecting mothers and their children, leading to the need for effective treatments.* -
- A phase 3 clinical trial tested zuranolone, a new drug, by comparing its effects to a placebo on women with PPD over a 2-week period.* -
- Results showed that zuranolone significantly reduced depression scores compared to placebo, indicating its potential efficacy and safety for treating PPD.*